Key facts
- Jocasta Neurosciences’s last known valuation is $52.0M (Aug 2025).
- It has raised $35.0M; the latest was Early Stage VC ($35.0M) in Aug 2025.
- Notable investors include True Ventures, Moore Strategic Ventures, JVC Investment Partners, Share Ventures, Yagan Family Foundation.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Jocasta Neurosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Jocasta Neurosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Jocasta Neurosciences
Operator of a biotech company intended to develop treat cognitive decline associated with various forms of dementia. The company focuses on a proprietary formulation of the protein alpha-Klotho, which has shown potential to slow cognitive decline in neurodegenerative diseases, enabling the medical industry to access suitable therapeutics that enhance cognitive function and lower the risk of Alzheimer's and other neurodegenerative diseases.
- Sector
- Healthcare
- HQ
- Northbrook, IL, United States
- Founded
- 2021
- Website
- jocastaneuro.com/
- Ownership
- Privately Held (backing)
Jocasta Neurosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Jocasta Neurosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Jocasta Neurosciences in its N-PORT filings yet. We sweep new filings monthly.